QC
EBS icon

Quantedge Capital’s Emergent Biosolutions EBS Stock Holding History

Quantedge Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-43,800
Closed -$366K – 158
2024
Q3 		$366K Buy
+43,800
New +$398K 0.11% 146
2022
Q3 		– Sell
-14,100
Closed -$438K – 231
2022
Q2 		$438K Buy
+14,100
New +$481K 0.09% 180

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Quantedge Capital's EBS Position: Q4 2024 in Review

Quantedge Capital sold out of Emergent Biosolutions (EBS) in Q4 2024, closing a stake of 43,800 shares — an estimated $366K sold.

Quantedge Capital first reported a position in EBS in Q2 2022 and held it in 2 quarters. The position peaked at $438K in Q2 2022. 156 funds tracked by Wall St. Rank hold EBS as of Q4 2024.

  • Quantedge Capital reported no remaining Emergent Biosolutions position as of Q4 2024 after selling out during the quarter.
  • Quantedge Capital sold 43,800 Emergent Biosolutions shares in Q4 2024, an estimated $366K.
  • Quantedge Capital first reported a position in Emergent Biosolutions in Q2 2022 and held it in 2 quarters.
  • Quantedge Capital's Emergent Biosolutions position peaked at $438K in Q2 2022.
  • 156 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2024.

Based on Quantedge Capital's 13F filing for Q4 2024, filed 14 Feb 2025.